Company Overview

PRIME exits and American Healthcare Capital are pleased to exclusively represent a rapidly growing, multi-state provider of Applied Behavior Analysis (ABA) therapy services focused on pediatric populations. Founded in 2020, the Company has developed a strong reputation for clinical excellence, scalable operations, and payer diversification, positioning it as an attractive platform for investors seeking exposure to the behavioral health sector.

The Company operates across three U.S. states with full Medicaid certification and commercial payer relationships, delivering individualized ABA therapy to children diagnosed with Autism Spectrum Disorder (ASD). Services are administered by a credentialed network of BCBAs and behavior technicians and include comprehensive behavioral assessments, treatment planning, family training, and virtual social skills groups. As of Q2 2025, the Company has over 180 active clients, with a consistent monthly intake of new patients and strong clinical throughput.

Financial Overview

With a highly efficient service delivery model and strong intake pipeline, the Company has experienced exceptional financial performance:

• 2022 Revenue: $2.5M | Adj. EBITDA: $570K

• 2023 Revenue: $4.5M | Adj. EBITDA: $947K

• 2024 Revenue: $6.7M | Adj. EBITDA: $1.4M

The Company maintains a favorable payer mix led by Medicaid (70%), with the balance from national commercial insurers including Aetna, UnitedHealthcare, BCBS, and Cigna. Its clean compliance record, credentialed staff, and multi-state licensure create a scalable foundation for geographic and service line expansion.

Exit Plan

The founder—an experienced clinician—has built a deep bench of operational talent and is open to remaining post-close to ensure a smooth transition. However, he is actively seeking a partner with the infrastructure and operating expertise to support the Company’s continued expansion.

Asking Price

This opportunity is ideally suited for platform acquisition by a behavioral health-focused private equity group or a strategic consolidator seeking to expand their pediatric therapy footprint with a high-performing, turnkey operation. The asking price is $10 million.